

Supplemental Appendix

Table of contents

| | |
|---|----|
| Supplemental Table 1 - Comparison Survivors versus Non-survivors..... | 2 |
| Supplemental Methods..... | 5 |
| Supplemental Table 2 - Comparison Spring Vs Winter..... | 6 |
| Supplemental Table 3 - Initial Laboratory Blood Tests..... | 9 |
| Supplemental Table 4 - Therapies Administered during the Admission | 11 |
| Supplemental Figure 1 - Distribution of Propensity Score | 12 |

Supplemental Table 1 - Comparison Survivors versus Non-survivors

| | Survivors (n=5953) | | Non-survivors (n=1437) | | p-value |
|---|--------------------|---------------------|------------------------|---------------------|---------|
| | Sample | Value | Sample | Value | |
| Demographics | | | | | |
| Age (IQR) - yr | 5953 | 64 (52 - 75) | 1437 | 73 (65 - 82) | <0.001 |
| Male sex - no (%) | 5953 | 2989 (50.2) | 1437 | 846 (58.9) | <0.001 |
| Black race and / or Hispanic ethnicity – no (%) | 5953 | 4472 (75.1) | 1437 | 1013 (70.5) | <0.001 |
| Body Mass Index (IQR) - kg/m ² | 5679 | 28.4 (24.6 - 33.2) | 1352 | 27.9 (23.8 - 32.6) | <0.001 |
| Hospital bed saturation (IQR) - % | 5953 | 94.1 (86.5 - 104.8) | 1437 | 99.3 (87.5 - 107.6) | <0.001 |
| Past Medical History | | | | | |
| Hypertension - no (%) | 5953 | 4365 (73.3) | 1437 | 1169 (81.4) | <0.001 |
| Sleep apnea - no (%) | 5953 | 688 (11.6) | 1437 | 178 (12.4) | 0.38 |
| Hyperlipidemia - no (%) | 5953 | 3366 (56.5) | 1437 | 975 (67.8) | <0.001 |
| Atrial fibrillation - no (%) | 5953 | 557 (9.4) | 1437 | 224 (15.6) | <0.001 |
| Chronic kidney disease - no (%) | 5953 | 1559 (26.2) | 1437 | 622 (43.3) | <0.001 |
| Heart failure - no (%) | 5953 | 1181 (19.8) | 1437 | 456 (31.7) | <0.001 |
| Coronary artery disease - no (%) | 5953 | 1653 (27.8) | 1437 | 587 (40.8) | <0.001 |
| Asthma/COPD - no (%) | 5953 | 1842 (30.9) | 1437 | 464 (32.3) | 0.32 |
| Diabetes mellitus - no (%) | 5953 | 3168 (53.2) | 1437 | 933 (64.9) | <0.001 |
| Vitals at Presentation | | | | | |
| Temperature (IQR) - F | 5926 | 99 (98 - 100) | 1427 | 99 (98 - 100) | 0.35 |
| SBP (IQR) - mmHg | 5932 | 132 (117 - 148) | 1430 | 127 (107 - 146) | <0.001 |

| | | | | | |
|--|------|--------------------|------|--------------------|--------|
| DBP (IQR) - mmHg | 5926 | 76 (67 - 85) | 1428 | 71 (60 - 81) | <0.001 |
| HR (IQR) – bpm | 5927 | 96 (83 - 110) | 1429 | 100 (85 - 114) | <0.001 |
| Oxygen saturation (IQR) - % | 5922 | 96 (93 - 98) | 1430 | 92 (84 - 96) | <0.001 |
| Respiratory Rate (IQR) - bpm | 5928 | 19 (18 - 21) | 1428 | 22 (19 - 26) | <0.001 |
| Laboratory Markers | | | | | |
| Hemoglobin (IQR) - g/dL | 5823 | 12.9 (11.4 - 14.1) | 1408 | 12.6 (10.9 - 14.2) | 0.006 |
| Platelet count (IQR) -k/ μ L | 5825 | 198 (137 - 264) | 1408 | 172 (88 - 246) | <0.001 |
| White blood cell count (IQR) - k/ μ L | 5823 | 6.9 (5.1 - 9.5) | 1408 | 8.3 (6.0 - 11.9) | <0.001 |
| Absolute lymphocyte count (IQR) - k/ μ L | 5880 | 1.1 (0.7 - 1.5) | 1423 | 0.9 (0.6 - 1.2) | <0.001 |
| Sodium (IQR) – mEq/L | 5879 | 137 (134 - 140) | 1428 | 138 (134 - 143) | <0.001 |
| Potassium (IQR) – mEq/L | 5845 | 4.2 (3.8 - 4.6) | 1426 | 4.4 (4.0 – 5.0) | <0.001 |
| Chloride (IQR) – mEq/L | 5864 | 100 (96 - 103) | 1423 | 100 (95 - 104) | 0.28 |
| Bicarbonates (IQR) – mEq/L | 5879 | 24 (21 - 27) | 1428 | 22 (18 - 25) | <0.001 |
| Creatinine (IQR) - mg/dL | 5876 | 1.0 (0.8 - 1.5) | 1427 | 1.6 (1 - 2.9) | <0.001 |
| Glucose (IQR) - mg/dL | 5879 | 126 (104 - 179) | 1428 | 156 (121 - 236) | <0.001 |
| Aspartate aminotransferase (IQR) - U/L | 5416 | 35 (24 - 55) | 1312 | 52 (33 - 81) | <0.001 |
| Alanine aminotransferase (IQR) - U/L | 5614 | 26 (16 - 42) | 1376 | 28 (18 - 46) | <0.001 |
| Lactic acid (IQR) – mmol/L | 5097 | 1.9 (1.4 - 2.6) | 1347 | 2.6 (1.8 - 3.9) | <0.001 |
| Lactate dehydrogenase (IQR) - mmol/L | 4017 | 384±219 | 926 | 518 (371 - 706) | <0.001 |
| Creatine Kinase (IQR) – U/L | 4714 | 336 (253 - 454) | 1218 | 777±2657 | <0.001 |
| D-dimer (IQR) - μ g/mL | 3850 | 1.2 (0.7 - 2.5) | 763 | 2.5 (1.3 - 6.9) | <0.001 |
| Procalcitonin (IQR) – ng/mL | 2800 | 0.1 (0.1 - 0.3) | 615 | 0.6 (0.2 - 2.4) | <0.001 |
| Troponin T* (IQR) - ng/mL | 2365 | 0.01 (0.01 - 0.03) | 302 | 0.03 (0.01 - 0.1) | <0.001 |
| Troponin I* (IQR) – ng/mL | 2684 | 0.01 (0.01 – 0.02) | 981 | 0.02 (0.01 - 0.08) | <0.001 |

| | | | | | |
|-----------------------------|------|------------------|-----|-------------------|--------|
| Interleukin-6 (IQR) – pg/mL | 1752 | 17 (6 - 40) | 287 | 68 (26- 154) | <0.001 |
| Fibrinogen (IQR) – mg/dL | 2478 | 570 (448 - 690) | 460 | 621 (506 - 761) | <0.001 |
| Ferritin (IQR) – ng/mL | 3395 | 521 (224 - 1112) | 659 | 1021 (514 - 2161) | <0.001 |

COPD = Chronic obstructive pulmonary disease; DBP = Diastolic blood pressure; HR = Heart rate; IQR = Interquartile range; SBP = Systolic blood pressure. * Troponin T was available only until June 2020, Troponin I was available only after June 2020.

Supplemental Methods

Covariate Selection Method for Multivariable Competing Risk Proportional Hazard Models for in-hospital Death between Patients Spring and Winter Patients

The covariates in the multivariable analyses included factors present in > 90% of our dataset, are known to be associated with in-hospital COVID-19 mortality based on prior literature or with a univariate association between admission season (exposure) or in-hospital mortality (outcome) ($p<0.05$) and a clinical (relative difference >5%) difference between the spring and winter patients (**Supplemental Table 2**). These variables included: age, sex, BMI, vital signs at presentation, white cell count, creatinine, glucose, alanine transaminase, history of hypertension, dyslipidemia, chronic kidney disease (CKD), heart failure, coronary artery disease, asthma/chronic obstructive pulmonary disease, diabetes mellitus and statin use. Also in this model, lactic acid level and percent of hospital bed saturation were forced into the model as marker of illness severity and level of hospital stress, respectively.

Supplemental Table 2 - Comparison Spring Vs Winter

| | Spring (n=4495) | | Winter (n=2254) | | p-value |
|---|-----------------|--------------------|-----------------|---------------------|---------|
| | Sample | Value | Sample | Value | |
| Demographics | | | | | |
| Age (IQR) - yr | 4495 | 66 (55 - 77) | 2254 | 67 (56 - 77) | 0.051 |
| Male sex - no (%) | 4495 | 2377 (52.9) | 2254 | 1122 (49.8) | 0.016 |
| Black race and / or Hispanic ethnicity – no (%) | 4495 | 3345 (74.4) | 2254 | 1635 (72.5) | 0.098 |
| Body Mass Index (IQR) - kg/m ² | 4229 | 28.4 (24.6 - 33) | 2194 | 28.2 (24.4 - 33.1) | 0.433 |
| Hospital bed saturation (IQR) - % | 4495 | 97.4 (86.5 – 107.6 | 2254 | 95.3 (91.9 – 101.8) | <0.001 |
| Past Medical History | | | | | |
| Hypertension - no (%) | 4495 | 3370 (75) | 2254 | 1713 (76) | 0.357 |
| Sleep apnea - no (%) | 4495 | 521 (11.6) | 2254 | 270 (12) | 0.640 |
| Hyperlipidemia - no (%) | 4495 | 2609 (58) | 2254 | 1380 (61.2) | 0.012 |
| Atrial fibrillation - no (%) | 4495 | 449 (10) | 2254 | 267 (11.8) | 0.019 |
| Chronic kidney disease - no (%) | 4495 | 1406 (31.3) | 2254 | 620 (27.5) | 0.001 |
| Heart failure - no (%) | 4495 | 980 (21.8) | 2254 | 519 (23) | 0.254 |
| Coronary artery disease - no (%) | 4495 | 1316 (29.3) | 2254 | 721 (32) | 0.022 |
| Asthma/COPD - no (%) | 4495 | 1371 (30.5) | 2254 | 753 (33.4) | 0.015 |
| Diabetes mellitus - no (%) | 4495 | 2522 (56.1) | 2254 | 1244 (55.2) | 0.475 |
| Vitals at Presentation | | | | | |
| Temperature (IQR) - F | 4463 | 98.9 (98.2 - 100) | 2254 | 98.7 (98.1 - 99.8) | <0.001 |
| SBP (IQR) - mmHg | 4469 | 131 (114 - 148) | 2254 | 132 (117 - 148) | 0.002 |
| DBP (IQR) - mmHg | 4465 | 75 (65 - 84) | 2252 | 75 (67 - 84) | 0.117 |
| HR (IQR) – bpm | 4467 | 98 (85 - 112) | 2253 | 95 (82 - 107) | <0.001 |

| | | | | | |
|--|------|--------------------|------|--------------------|--------|
| Oxygen saturation (IQR) - % | 4463 | 95 (91 - 98) | 2253 | 96 (92 - 98) | <0.001 |
| Respiratory Rate (IQR) - bpm | 4466 | 20 (18 - 22) | 2254 | 19 (18 - 22) | <0.001 |
| Laboratory Markers | | | | | |
| Hemoglobin (IQR) - g/dL | 4372 | 12.8 (11.2 - 14.1) | 2228 | 12.9 (11.5 - 14.2) | 0.030 |
| Platelet count (IQR) - k/ μ L | 4372 | 188 (116 - 260) | 2228 | 196 (143 - 259) | <0.001 |
| White blood cell count (IQR) - k/ μ L | 4372 | 7.5 (5.6 - 10.6) | 2228 | 6.4 (4.7 - 8.8) | <0.001 |
| Absolute lymphocyte count (IQR) - k/ μ L | 4420 | 1 (0.7 - 1.4) | 2246 | 1 (0.7 - 1.4) | 0.062 |
| Sodium (IQR) – mEq/L | 4414 | 137 (134 - 141) | 2253 | 137 (134 - 140) | <0.001 |
| Potassium (IQR) – mEq/L | 4389 | 4.3 (3.9 - 4.8) | 2243 | 4.1 (3.8 - 4.5) | <0.001 |
| Chloride (IQR) – mEq/L | 4394 | 98 (95 - 103) | 2253 | 101 (98 - 104) | <0.001 |
| Bicarbonates (IQR) – mEq/L | 4414 | 24 (20 - 26) | 2253 | 24 (21 - 27) | <0.001 |
| Creatinine (IQR) - mg/dL | 4410 | 1.1 (0.8 - 2) | 2253 | 1.1 (0.8 - 1.5) | <0.001 |
| Glucose (IQR) - mg/dL | 4414 | 134 (108 - 197) | 2253 | 126 (104 - 184) | <0.001 |
| Aspartate aminotransferase (IQR) - U/L | 4045 | 40 (27 - 65) | 2084 | 35 (24 - 55) | <0.001 |
| Alanine aminotransferase (IQR) - U/L | 4206 | 27 (17 - 44) | 2171 | 26 (17 - 44) | 0.292 |
| Lactic acid (IQR) – mmol/L | 3981 | 2.1 (1.6 - 3) | 1913 | 1.9 (1.4 - 2.5) | <0.001 |
| Lactate dehydrogenase (IQR) - mmol/L | 2935 | 384 (285 - 535) | 1563 | 341 (254 - 468) | <0.001 |
| Creatine Kinase (IQR) – U/L | 3453 | 168 (83 - 401) | 1957 | 126 (67 - 282) | <0.001 |
| D-dimer (IQR) - μ g/mL | 2204 | 1.8 (0.9 - 3.9) | 1907 | 1.2 (0.7 - 2.3) | <0.001 |
| Procalcitonin (IQR) – ng/mL | 1789 | 0.2 (0.1 - 0.9) | 1252 | 0.1 (0.1 - 0.3) | <0.001 |
| Troponin T* (IQR) - ng/mL | 0 | NA | 2106 | 0.01 (0.01 - 0.03) | NA |
| Troponin I* (IQR) – ng/mL | 3662 | 0.01 (0.01 - 0.03) | 0 | NA | NA |
| Interleukin-6 (IQR) – pg/mL | 1056 | 34 (14 - 75) | 710 | 11 (4 - 26) | <0.001 |
| Fibrinogen (IQR) – mg/dL | 1552 | 624 (491 - 750) | 1040 | 536 (434 - 652) | <0.001 |

| | | | | | |
|------------------------|------|------------------|------|------------------|--------|
| Ferritin (IQR) – ng/mL | 1969 | 716 (335 - 1498) | 1637 | 510 (230 - 1094) | <0.001 |
|------------------------|------|------------------|------|------------------|--------|

COPD = Chronic obstructive pulmonary disease; DBP = Diastolic blood pressure; HR = Heart rate; IQR = Interquartile range; SBP = Systolic blood pressure. * Troponin T was available only until June 2020, Troponin I was available only after June 2020.

Supplemental Table 3 - Initial Laboratory Blood Tests

| | Spring (n=4495) | Summer (n=264) | Fall (n=377) | Winter (n=2254) |
|--|------------------------|-----------------------|---------------------|------------------------|
| Hemoglobin (IQR) - g/dL | 12.8 (11.2 - 14.1) | 12.4 (10.7 - 13.9) | 13 (11.6 - 14.3) | 12.9 (11.5 - 14.2) |
| Platelet count (IQR) - k/ μ L | 188 (116 - 260) | 228 (169 - 300) | 200 (144 - 257) | 196 (143 - 259) |
| White blood cell count (IQR) - k/ μ L | 7.5 (5.6 - 10.6) | 8 (5.8 - 11) | 6.6 (5.1 - 8.9) | 6.4 (4.7 - 8.8) |
| Absolute lymphocyte count (IQR) - k/ μ L | 1 (0.7 - 1.4) | 1.2 (0.9 - 1.8) | 1.1 (0.8 - 1.5) | 1 (0.7 - 1.4) |
| Sodium (IQR) - mEq/L | 137 (134 - 141) | 138 (135 - 141) | 137 (135 - 140) | 137 (134 - 140) |
| Potassium (IQR) - mEq/L | 4.3 (3.9 - 4.8) | 4.2 (3.8 - 4.6) | 4 (3.8 - 4.4) | 4.1 (3.8 - 4.5) |
| Chloride (IQR) - mEq/L | 98 (95 - 103) | 103 (100 - 105) | 101 (99 - 104) | 101 (98 - 104) |
| Bicarbonates (IQR) - mEq/L | 24 (20 - 26) | 24 (21 - 27) | 25 (22 - 27) | 24 (21 - 27) |
| Creatinine (IQR) - mg/dL | 1.1 (0.8 - 2) | 1 (0.8 - 1.5) | 1 (0.8 - 1.3) | 1.1 (0.8 - 1.5) |
| Glucose (IQR) - mg/dL | 134 (108 - 197) | 121 (100 - 171) | 122 (102 - 173) | 126 (104 - 184) |
| Aspartate aminotransferase (IQR) - U/L | 40 (27 - 65) | 26 (20 - 38) | 31 (21 - 47) | 35 (24 - 55) |
| Alanine aminotransferase (IQR) - U/L | 27 (17 - 44) | 21 (14 - 32) | 25 (16 - 41) | 26 (17 - 44) |
| Lactic acid (IQR) - mmol/L | 2.1 (1.6 - 3) | 1.9 (1.4 - 2.7) | 1.8 (1.3 - 2.5) | 1.9 (1.4 - 2.5) |
| Lactate dehydrogenase (IQR) - mmol/L | 384 (285 - 535) | 254.5 (196 - 340) | 300 (225 - 383) | 341 (254 - 468) |
| Creatine Kinase (IQR) - U/L | 168 (83 - 401) | 97 (57 - 176) | 116 (60 - 213) | 126 (67 - 282) |
| D-dimer (IQR) - μ g/mL | 1.8 (0.9 - 3.9) | 1.1 (0.5 - 2.2) | 0.8 (0.5 - 1.6) | 1.2 (0.7 - 2.3) |
| Procalcitonin (IQR) - ng/mL | 0.2 (0.1 - 0.9) | 0.1 (0.1 - 0.4) | 0.1 (0.1 - 0.2) | 0.1 (0.1 - 0.3) |
| Troponin T* (IQR) - ng/mL | NA | 0.01 (0.01 - 0.03) | 0.01 (0.01 - 0.02) | 0.01 (0.01 - 0.03) |
| Troponin I* (IQR) - ng/mL | 0.01 (0.01 - 0.03) | 0.01 (0.01 - 0.01) | NA | NA |
| Interleukin-6 (IQR) - pg/mL | 33.6 (13.8 - 75.2) | 11.7 (3 - 43.1) | 11 (4.7 - 22.2) | 10.8 (4.3 - 25.6) |
| Fibrinogen (IQR) - mg/dL | 624 (491 - 750) | 448 (370- 583) | 540 (436 - 663) | 535.5 (434 - 652) |


| | | | | |
|------------------------|------------------|----------------|-----------------|------------------|
| Ferritin (IQR) – ng/mL | 716 (335 - 1498) | 228 (90 - 562) | 364 (166 - 785) | 510 (230 - 1094) |
|------------------------|------------------|----------------|-----------------|------------------|

IQR = Interquartile range. * Troponin T was available only until June 2020, Troponin I was available only after June 2020

Supplemental Table 4 - Therapies Administered during the Admission

| | Spring (n=4495) | Summer (n=264) | Fall (n=377) | Winter (n=2254) |
|--|----------------------------|---------------------------|-------------------------|----------------------------|
| Hydroxychloroquine - no (%) | 3007 (66.9) | 1 (0.4) | 2 (0.5) | 8 (0.4) |
| Azithromycin - no (%) | 1322 (29.4) | 51 (19.3) | 118 (31.3) | 374 (16.6) |
| Other antibiotics - no (%) | 3382 (75.2) | 160 (60.6) | 214 (56.8) | 1082 (48) |
| Steroids - no (%) | 1485 (33) | 71 (26.9) | 195 (51.7) | 1462 (64.9) |
| Angiotensin-converting-enzyme Inhibitors - no (%) | 318 (7.1) | 36 (13.6) | 51 (13.5) | 269 (11.9) |
| Angiotensin II receptor blockers - no (%) | 264 (5.9) | 23 (8.7) | 32 (8.5) | 212 (9.4) |
| Statin - no (%) | 1478 (32.9) | 109 (41.3) | 129 (34.2) | 1002 (44.5) |
| Therapeutic anticoagulation - no (%) | 1041/4496 (31.2) | 76 (28.8) | 98 (26.0) | 772 (34.3) |
| Remdesivir* - no (%) | 78 (1.7) | 37 (14) | 134 (35.5) | 1224 (54.3) |
| Lopinavir/Ritonavir – no (%) | 40 (0.9) | 0 (0) | 0 (0) | 0 (0) |
| Ivermectin – no (%) | 11 (0.2) | 1 (0.4) | 0 (0) | 34 (1.5) |

* 45 patients listed as remdesivir recipients in the spring season were part of a 1:1 double-blind, placebo-controlled study. Instead, all the patients in summer, fall, and winter seasons listed as remdesivir recipients received the actual medication.

Supplemental Figure 1 - Distribution of Propensity Score

AST = aspartate transaminase; BMI= body mass index; CAD= coronary artery disease; COPD = chronic obstructive pulmonary disease; CKD = chronic kidney disease; DBP= diastolic blood pressure; DM = Diabetes mellitus; HF= heart failure; HLD = hyperlipidemia; HNT = hypertension; HR = heart rate; SBP = systolic blood pressure; WBC = white blood cell count